By Ellen Prediger, PhD, Director, Scientific Communication, and Kathy Latham, PhD, Marketing Manager, Ambion, Inc.
QIAGEN continually expands and develops the range of products and services available to incorporate newly developing technologies and to facilitate research and discovery in the fast-moving life sciences area.
Medicinal chemistry continues to be confronted with new opportunities to explore and refine the predictive potential of drug design.
Colin Dykes, Chief Scientific Officer and Executive Vice-President of Corporate Development, OpGen, gives us the lowdown on the importance of optical mapping in healthcare and what’s next for the technology.
Tissue, disease and species specificity testing of potential candidate biomarkers using expression profiling.